Boston Scientific Corporation vs Lumen Technologies Inc — how do they compare? Boston Scientific Corporation trades at $43.29 (market cap $66.37B), while Lumen Technologies Inc trades at $6.38 (market cap $6.56B). The key difference: Boston Scientific Corporation is far larger — about 10.1× Lumen Technologies Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | LUMN | |
|---|---|---|
Market Cap | $66.37B | $6.56B |
Sector | Health | Media |
52-Week High | $108.14 | $11.83 |
52-Week Low | $42.63 | $3.70 |
Enterprise Value | $75.94B | $18.19B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
LUMN trades at $6.45, down 4.16% today, reflecting ongoing investor caution amid a bearish technical signal. The company reported a net loss of $1.74 billion in 2025 despite beating earnings expectations in two of the last three quarters. Recent news highlights strategic moves like the Alkira acquisition to bolster its AI networking platform. Cash flow from operations remains strong at $4.74 billion, but high debt levels and negative profitability metrics pose challenges.
The outlook is mixed; cost-cutting and a $13 billion contract backlog offer potential upside, but persistent losses and a heavy debt load of $17.49 billion limit near-term growth. Analyst consensus is cautious with a hold-heavy rating, though the $8.25 price target implies modest upside from current levels if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →